Loading stock data…
SKIN
$0.90+0.04 (+4.22%)
Market ClosedLast close May 4
The Beauty Health Company, a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SkinHealth Systems Inc. in the Consumer Defensive sector is trading at $0.90. The stock is currently near its 52-week low of $0.76, remaining 38.8% below its 200-day moving average. Technical signals show neutral RSI of 40 and bullish MACD crossover, explaining why SKIN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.90
Potential Upside
5%
Whystock Fair Value$0.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$1.61+78.7%
Range$1.00 – $2.50
Fundamentals
The Beauty Health Company, a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship pro...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.36M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.13%
Volume
Today's trading volume
1.37M
Recent News
Consumer Staples Aren’t So Defensive Anymore. Even Grocery Outlet and BellRing Are Volatile.
Consumer staples stocks like Grocery Outlet and BellRing are showing unexpected volatility in 2026, challenging the sector’s reputation as a safe haven.
How The Beauty Health (SKIN) Investment Story Is Shifting With Mixed Analyst Signals
Beauty Health’s latest analyst update comes with a trimmed price target, with some bullish researchers moving from US$1.65 to US$1.50 while model fair value holds at US$1.69. That shift lines up with commentary that Q4 outperformance and FY26 EBITDA guidance are being weighed against softer near term distributor orders and execution questions. As you read on, you will see how these mixed signals are shaping the evolving narrative around risk, reward, and what to watch next. Stay updated as...
Why The Beauty Health Story Is Shifting As Analysts Rework Targets And FY26 EBITDA Expectations
Beauty Health is back in focus as analysts trim their price target from US$1.65 to US$1.50, while a separate fair value estimate is reset from US$1.93 to US$1.69. The shift reflects fresh reactions to the Q4 report, where views are split between confidence in the FY26 EBITDA guidance and concerns around softer near term distributor trends and macro related pressures. In the sections that follow, you will see how these moving targets shape the evolving narrative around risk, reward, and what...
Don't Overlook Beauty Health (SKIN) International Revenue Trends While Assessing the Stock
Evaluate Beauty Health's (SKIN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
The Beauty Health Company Q4 2025 Earnings Call Summary
Moby summary of The Beauty Health Company's Q4 2025 earnings call